PROXENTIA SRL

Their core work

Proxentia is a Milano-based deep-tech SME built around a proprietary optical biosensor platform called Reflective Phantom Interface (RPI). Their core business is developing rapid, multiplexed detection systems that can identify food contaminants and pathogens directly at the point of need — without laboratory infrastructure. They combine advanced surface functionalization and nano-coating chemistry with photonic sensing to create practical food safety instruments. Their H2020 track record shows a company that successfully took a technology from feasibility proof (Phase 1) to full commercial development (Phase 2), suggesting they are past the pure research stage and oriented toward market deployment.

What they specialise in

How they've shifted over time

Proxentia's H2020 participation is essentially one technology story told in two chapters. The Phase 1 project (2014–2015) was a feasibility exercise with no detailed technical keywords — a signal that the concept was still being validated. By Phase 2 (2016–2018), the technical vocabulary sharpens dramatically: surface functionalization, multiplexing, advanced coatings, and the RPI platform name all appear, indicating the technology had matured into an engineered system. There is no data beyond 2018, so it is unclear whether they pursued further EU funding or pivoted to private commercialization after the SME Instrument cycle concluded.

Proxentia appears to be a company that used EU funding as a structured commercialization runway — moving from concept to prototype — and any future collaboration would likely involve integrating their RPI sensing platform into new application areas such as environmental monitoring, clinical diagnostics, or veterinary testing.

How they like to work

Proxentia acts exclusively as consortium coordinator, never as a junior partner — both projects were led by them. Their consortia are extremely small (3 unique partners across 2 countries), which is typical of SME Instrument projects where the company is the primary innovator and external partners play supporting roles. This profile suggests they are a technology owner seeking application partners or distribution channels, not a service provider looking to join large multi-partner consortia.

Proxentia's network is minimal by EU standards — 3 partners across 2 countries over its entire H2020 history. This reflects the SME Instrument model rather than a broad collaborative network, and the company likely relies on bilateral relationships rather than consortium ecosystems.

What sets them apart

Proxentia's differentiator is the RPI platform itself — a proprietary label-free optical biosensor technology that, if validated at the claimed performance level, enables rapid on-site detection without the reagent costs and lab infrastructure of conventional immunoassay methods. For a potential partner, this means access to a specific sensing IP rather than generic analytical chemistry expertise. However, with only two completed projects and no published network beyond Italy, due diligence on current commercialization status is essential before building a consortium around them.

Highlights from their portfolio

• STEFY
  The Phase 2 project (€761,915, 2016–2018) represents one of the larger SME Instrument Phase 2 awards in food safety sensing and demonstrates that an independent European evaluator judged the RPI technology commercially viable enough for full development funding.
• Stefy
  The Phase 1 project (€50,000, 2014–2015) is notable as the proof-of-concept milestone that unlocked the larger Phase 2 grant, confirming a successful two-stage EU validation of the technology.